Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of “Reduce” by Analysts

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received a consensus rating of “Reduce” from the eight brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $24.00.

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Barclays decreased their price target on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AMPH. Marshall Wace LLP lifted its position in shares of Amphastar Pharmaceuticals by 41.6% in the 4th quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after purchasing an additional 363,216 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Amphastar Pharmaceuticals by 382.9% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 392,310 shares of the company’s stock valued at $10,455,000 after acquiring an additional 311,071 shares during the period. Clark Capital Management Group Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at $7,560,000. Algert Global LLC lifted its position in shares of Amphastar Pharmaceuticals by 216.1% during the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock valued at $10,471,000 after acquiring an additional 268,612 shares during the period. Finally, UBS Group AG lifted its position in shares of Amphastar Pharmaceuticals by 367.2% during the 3rd quarter. UBS Group AG now owns 312,274 shares of the company’s stock valued at $8,322,000 after acquiring an additional 245,440 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $18.81 on Monday. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $31.26. The firm has a market cap of $829.33 million, a P/E ratio of 11.33, a P/E/G ratio of 3.70 and a beta of 0.91. The company’s 50-day moving average price is $19.97 and its two-hundred day moving average price is $23.07.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.28). The firm had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. On average, analysts anticipate that Amphastar Pharmaceuticals will post 2.41 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.